Know Cancer

forgot password

Spectral Markers in Aspirin Chemoprevention of Colonic Neoplasia

Phase 2
75 Years
Open (Enrolling)
Colon Cancer, Precancerous Condition, Rectal Cancer

Thank you

Trial Information

Spectral Markers in Aspirin Chemoprevention of Colonic Neoplasia


I. Determine whether acetylsalicylic acid (aspirin) will alter spectral markers (i.e.,
spectral slope and fractal dimension) in distal colonic mucosa of patients who are at
increased risk for the development or recurrence of colorectal cancer.


I. Assess the effect of this drug on colonic epithelial apoptosis and cell proliferation in
these patients.

II. Assess the effect of this drug on rectal prostaglandin levels in these patients.

III. Assess the effect of this drug on platelet cyclooxygenase activity in these patients.

IV. Correlate changes in spectral markers with UGT1A6 genotype in patients treated with this

OUTLINE: This is a multicenter, randomized, double-blind, placebo-controlled study. Patients
are stratified by clinical site and adenoma/carcinoma maximal size. Patients with abnormal
spectral biomarkers are randomized to 1 of 2 treatment arms.

ARM I: Patients receive oral acetylsalicylic acid (aspirin) once daily.

ARM II: Patients receive oral placebo once daily.

In both arms, treatment continues for 3 months in the absence of unacceptable toxicity.

Patients undergo flexible sigmoidoscopy and biopsies as well as blood collection at baseline
(during prestudy colonoscopy) and at completion of study treatment for comparison of
spectral signatures with biomarkers of both aspirin activity (including plasma
cyclooxygenase activity and rectal prostaglandin levels) as well as with biomarkers
associated with antineoplastic alteration (including apoptosis and cell proliferation).
UGT1A6 genotyping analysis is also performed.

After completion of study treatment, patients are followed at 3 months.

Inclusion Criteria


- No active or metastatic cancer within the past 6 months

- Scheduled to undergo colonoscopy for colonic neoplasia surveillance

- Hemoglobin >= 12.0 g/dL

- Platelet count >= 120,000/mm^3

- AST or ALT =< 1.5 times upper limit of normal (ULN)

- Alkaline phosphatase =< 1.5 times ULN

- Bilirubin =< 1.5 times ULN

- BUN =< 40 mg/dL

- Glomerular filtration rate >= 45 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No coagulopathy

- No anemia

- No history of peptic ulcer disease or gastrointestinal hemorrhage

- No history of cerebrovascular accident

- No uncontrolled hypertension

- No history of intolerance or allergy to aspirin or to NSAIDs

- No liver disease as manifested by signs or symptoms of cirrhosis

- No endoscopic or radiographic evidence of portal hypertension

- No active colitis by endoscopy

- No history of inflammatory bowel disease

- No requirement for aspirin as medical therapy (i.e., post-myocardial infarction or
transient ischemic attack)

- No untreated helicobacter pylori infection

- History of significant colonic neoplasia, defined as 1 of the following:

- Adenoma within the past 6 years

- Colorectal cancer within the past 6 years

- Known adenoma on present exam

- Histologically confirmed polyps seen on imaging

- INR =< 1.5

- At least 6 months since prior cancer treatment

- No other concurrent acetylsalicylic acid (aspirin)-containing products or
non-steroidal anti-inflammatory drugs (NSAIDs)

- No concurrent systemic corticosteroids

- No other concurrent anticoagulants or antiplatelet agents

- No concurrent investigational drugs

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Outcome Measure:

Change in spectral slope

Outcome Description:

The difference in the observed change from baseline in each arm, aspirin and placebo, will be compared.

Outcome Time Frame:

From baseline to 3 months after completion of study treatment

Safety Issue:


Principal Investigator

Hemant Roy

Investigator Role:

Principal Investigator

Investigator Affiliation:

Northwestern University


United States: Institutional Review Board

Study ID:




Start Date:

March 2007

Completion Date:

Related Keywords:

  • Colon Cancer
  • Precancerous Condition
  • Rectal Cancer
  • Colonic Neoplasms
  • Rectal Neoplasms
  • Colorectal Neoplasms
  • Precancerous Conditions



Northwestern University Chicago, Illinois  60611